She has heavy bleeding due to fibroids

She doesn’t currently want surgery

Her one goal

Quickly take the heavy out of menstrual bleeding

1st Icon.

The first oral treatment specifically indicated for heavy menstrual bleeding due to uterine fibroids in premenopausal women1

Over 50% average bleeding reduction seen at Month 12
3 out of 395 women taking ORIAHNN discontinued for fibroid surgery in the 6-month clinical trials3
Get patients started with support & savings
Measuring Cup Icon.

ORIAHNN was proven to reduce heavy menstrual bleeding.1

Clipboard and magnifying glass Icon.

ORIAHNN results were analyzed across multiple subgroups including fibroid size and location4

Silverware Icon.

ORIAHNN can be taken with or without food to help fit into her schedule1

Give every UF patient a free trial* of ORIAHNN with Oriahnn Complete

Help her enroll in Oriahnn Complete to activate her free trial

Fill out

Download and complete this

with your patient to access a 28-day trial supply, so she has the opportunity to try treatment for free.* Then, you can both decide if continuing ORIAHNN is still the right choice for her.



Fax the form to 1-855-662-5355.

An Oriahnn Complete Access Specialist will contact your office with next steps.

She's enrolled!

Give your patient the Patient Welcome Sheet.

Starting your patient on the free trial? We’ll call to confirm shipping details.

Pill packaging Icon.

Give every patient a free trial* of ORIAHNN with Oriahnn Complete

Once enrolled, a free 28-day trial supply of ORIAHNN will be shipped quickly, directly to her. Then, you can both decide if continuing on ORIAHNN is still the right choice for her.

Get your patients the support they need to start and stay on track with their prescribed ORIAHNN treatment plan

Download the Oriahnn Complete Enrollment & Prescription Form

OR for any enrollment questions call 1-800-ORIAHNN (1-800-674-2466)

*The ORIAHNN free trial provides a single 28-day trial supply of ORIAHNN at no cost to new patients residing in the United States with a valid prescription for an FDA-approved indication of ORIAHNN and who enroll in Oriahnn Complete. The trial is intended solely to allow new patients not currently taking ORIAHNN to determine with their healthcare provider whether ORIAHNN is right for them. There is no obligation to continue use of ORIAHNN after the trial has concluded and this program does not guarantee insurance coverage. Eligible patients are limited to one 28-day trial supply and may not re-enroll. The ORIAHNN trial supply will be dispensed only through an AbbVie-authorized pharmacy to the patient’s home address and may not be sold or further distributed. No claims for payment may be submitted to any third party insurance plan for product dispensed by program. AbbVie reserves the right to change or discontinue the trial at any time without notice. The trial is not health insurance and is not a discount, coupon, rebate or financial assistance program. Limitations may apply.